Gland Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported over 4-fold jump in its net profit at Rs 321.41 crore for the quarter under review as compared to Rs 79.21 crore for the same quarter in the previous year. Even, the total income of the company increased by 48.21% at Rs 1221.79 crore for Q4FY24 as compared Rs 824.36 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported almost two and a half fold jump in its net profit at Rs 192.42 crore for fourth quarter ended March 31, 2024 as compared to Rs 78.68 crore for the same quarter in the previous year. Total income of the company increased by 91.71% at Rs 1579.59 crore for Q4FY24 as compared Rs 823.95 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported 34.48% rise in its net profit at Rs 1043.33 crore as compared to Rs 775.83 crore for the previous year. Total income of the company increased by 12.37% at Rs 4334.09 crore for year under review as compared to Rs 3856.99 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported 1.09% fall in its net profit at Rs 772.46 crore as compared to Rs 781.04 crore for the previous year. Total income of the company increased by 50.97% at Rs 5834.96 crore for year under review as compared to Rs 3865.06 crore for year ended March 31, 2023.